K.V. GUBSKAIA, L.V. SINITSYNA

 Ivanovo State Medical University, Ivanovo

 Contact details:

Sinitsyna L.V. — PhD (Medicine), Head of the Center for multiple sclerosis

Address: 8 Sheremetevskiy prospekt, Ivanovo, Russian Federation, 153012, tel.: +7-961-117-59-22, e-mail: SinitsinaLV@ya.ru

 Up to 50% of patients with multiple sclerosis (MS) suffer from mental disorders.

The purpose — to study the risk factors for mental disorders development in MS patients.

Material and methods. The study group included 315 patients with MS and mental disorders. The control group consisted of 300 MS patients without mental disorders. The diagnosis of MS was established according to the 2017 McDonald criteria. The diagnosis of mental disorders was established in accordance with the ICD-10 criteria. We used Beck Depression Inventory (BDI), Multidimensional Fatigue Inventory (MFI-20), Spielberger State-Trait Anxiety Inventory (STAI), adapted by Khanin, Expanded Disability Status Scale (EDSS), and Holmes and Rahe stress scale. MS progression rate (PR) was calculated using N. A. Malkova (1988) method.

Results. The research established a link between mental disorders development and the localization of demyelination foci, with MS PR of at least 0.74 EDSS points per year, and with significant stressful events before MS development.

Conclusion. The data obtained can be used to predict the development of mental disorders in MS patients.

Key words: multiple sclerosis, localization of foci in the brain, progression rate, significant stressful events.

REFERENCES

1. Artemiadis A.K., Anagnostouli M.C., Alexopoulos E.C. Stress as a risk factor for multiple sclerosis onset or relapse: A systematic review. Neiroepidemiology, 2011, vol. 36, pp. 109–120.
2. Ebers G.C., Yee I.M., Sadovnick A.D. et al. Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann. Neurol, 2000, vol. 48, pp. 927–931.
3. Trask P.C., Esper P., Riba M., Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J. Clin. Oncol, 2000, vol. 18 (11), pp. 2316–2326. DOI: 10.1200/JCO.2000.18.11.2316
4. Lukina E.V., Kuznetsova D.E. Assessment of the level of anxiety and depression in patients with multiple sclerosis. Saratovskiy nauchno-meditsinskiy zhurnal, 2012, vol. 8, no. 2, pp. 484–488 (in Russ.).
5. Kotov S.V., Yakushina T.I., Lizhdvoy V.Yu. Treatment of exacerbations of multiple sclerosis. Effective pharmacotherapy. Nevrologiya i psikhiatriya, 2010, no. 1, pp. 22–25 (in Russ.).
6. Shmidt Т.Ye., Yakhno N.N. Rasseyannyy skleroz: rukovodstvo dlya vrachey. 3-e izd. [Multiple sclerosis: a guide for doctors. 3rd ed.]. Moscow: Medpress-inform, 2012. 272 p.
7. Lyoo I., Seol H., Byun P., Renshaw P. Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. J. Neuropsychiatry Clin. Neirosci, 1996, vol. 8 (1), p. 54. DOI: 10.1176/jnp.8.1.54
8. Feinstein A. The clinical neuropsychiatry of multiple sclerosis. Cambridge Medicine. Toronto: Cambridge University Press, 2007.
9. Mantero V., Abate L., Balgera R., La Mantia L., Salmaggi A. Clinical application of 2017 McDonald diagnostic criteria for multiple sclerosis. J. Clin. Neurol, 2018, vol. 14 (3), pp. 387–392. DOI: 10.3988/jcn.2018.14.3.387
10. Edwards R.R., Dworkin R.H., Sullivan M.D. et al. The role of psychosocial processes in the development and maintenance of chronic pain. J. Pain, 2016, vol. 17 (9), pp. T70-92. DOI: 10.1016/j.jpain.2016.01.001
11. Yakushina T.I., Belova Yu.A. Psychotic disorders in multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2018, vol. 118, pp. 110–115 (in Russ.).
12. Holmes T.H., Rahe R.H. The social readjustment rating scale. J. Psychosom. Res, 1967, vol. 11(2), pp. 213–218. DOI: 10.1016/0022-3999(67)90010-4
13. Kang J.H., Chen Y.H., Lin H.C. Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur. J. Neurol, 2010, vol. 17, pp. 1215–1219.
14. Beck A., Ward C., Mendelson M. An inventory for measuring depression. Arch. Gen. Psychat, 1961, vol. 4, pp. 561–571.
15. Khanin Yu.L. Kratkoe rukovodstvo k primeneniyu shkaly reaktivnoy i lichnostnoy trevozhnosti Ch.D. Spilbergera [A brief guide to the use of the scale of reactive and personal anxiety by Ch.D. Spielberger]. Leningrad, 1976. 40 p.
16. Smets E.M.A., Garssen B., Bonke B., De Haes J.C. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res, 1995, vol. 39, pp. 315–325.
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expandeddisability status scale (EDSS). Neurology, 1983, vol. 33, 1444e52.
18. Malkova N.A., Ierusalimskiy A.P. Rasseyannyy skleroz [Multiple sclerosis]. Novosibirsk: Gos. med. un-t MZ i SR RF, 2006
19. Huitinga I., Erkut Z.A., van Beurden D., Swaab D.F. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann. Neurol, 2004, vol. 55 (1), pp. 37–45. DOI: 10.1002/ana.10766. PMID: 14705110
20. Kurtzke J.F., Roxburgh R.H., Seaman S.R., Masterman T. et al. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983;33:1444e52.
21. Silveira C., Guedes R., Maia D., Curral R., Coelho R. Neuropsychiatric symptoms of multiple sclerosis: state of the art. Psychiatry Investig, 2019, vol. 16 (12), pp. 877–888. DOI: 10.30773/pi.2019.0106
22. Panda S.P., Das R.C., Srivastava K., Ratnam A., Sharma N. Psychiatric comorbidity in multiple sclerosis. Neurol. Neurochir. Pol, 2018, vol. 52 (6), pp. 704–709. DOI: 10.1016/j.pjnns.2018.09.003
23. Gay M.C., Bungener C., Thomas S. et al. Anxiety, emotional processing and depression in people with multiple sclerosis. BMC Neurol, 2017, vol. 17 (1), pp. 43. DOI: 10.1186/s12883-017-0803-8